Extending the MIS BAIR randomised trial of BCG to prevent childhood allergy and infection

扩展 BCG 预防儿童过敏和感染的 MIS BAIR 随机试验

• 批准号: nhmrc : GNT1099676
• 负责人: A/Pr Katie Flanagan
• 金额: $ 93.95万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/extending-mis-bair-allergy-infection/1346075
• 关键词: Extending; MIS; BAIR; randomised; trial

BCG (used till recently to prevent tuberculosis) is a potential low cost and readily available vaccine which could reduce the rates of allergy and infection in Australian children. We propose to extend our existing NHMRC-funded trial, which studies whether BCG vaccinatinon given at birth prevents the development food allergy, eczema and infection in the 1st year of life, to see if this effect continues until 5yrs of age. At this age, we can also see if BCG vaccination at birth prevents asthma.

卡介苗（直到最近还用于预防结核病）是一种潜在的低成本和容易获得的疫苗，可以降低澳大利亚儿童的过敏和感染率。我们建议扩展我们现有的NHMRC资助的试验，该试验研究出生时接种BCG疫苗是否可以预防出生后第一年的食物过敏，湿疹和感染，看看这种效果是否会持续到5岁。在这个年龄，我们还可以看到出生时接种卡介苗是否可以预防哮喘。